文献速递糖尿病

暂停预授权对弱势人群糖尿病技术可及性的影响:回顾性分析

Impact of Prior Authorization Suspension on Access to Diabetes Technology in an Underserved Population: A Retrospective Analysis.
PubMed 文献 · Diabetes Care · 2026-01-01

研究回顾性分析105例安全网诊所1型糖尿病成人,比较需预授权与免预授权两个政策阶段。免预授权期CGM使用率从36.2%升至81.0%,泵使用从16例增至25例,平均HbA1c从9.1%(76 mmol/mol)降至8.5%(69 mmol/mol)(P=0.032)。取消预授权要求与糖尿病技术可及性改善及有临床意义的HbA1c下降相关,但残余障碍仍存。

要点

  • 免预授权期CGM使用率从36.2%升至81.0%,泵使用从16例增至25例。
  • 平均HbA1c从9.1%(76 mmol/mol)降至8.5%(69 mmol/mol),P=0.032。
  • 预授权期CGM处方延迟占46%、拒绝占21%,免预授权期平均延迟降至40天但仍存在。

核心结论

  • 取消预授权要求与糖尿病技术可及性改善及有临床意义的HbA1c下降相关。
  • 残余障碍凸显持续的结构性不平等。
  • 研究结果支持减少临床指征人群行政负担的政策。

研究设计与样本

  • 回顾性病历审查,纳入安全网诊所105例1型糖尿病成人。
  • 比较两个连续政策阶段:需预授权期与免预授权期。
  • 观察性结局包括设备处方、延迟、拒绝、设备获取及HbA1c。
  • 配对t检验(α=0.05)评估HbA1c变化,描述性统计总结可及性。
  • 延迟和可及性结局定义预先标准化。

主要发现

  • 需预授权期开具32份CGM处方,46%延迟(平均82天),21%被拒绝。
  • 免预授权期开具27份新CGM处方,批准增加,平均延迟降至40天,但延迟仍持续。
  • CGM使用率从36.2%增至81.0%,泵使用从16例增至25例。
  • 平均HbA1c从9.1%(76 mmol/mol,SD=2.16)降至8.5%(69 mmol/mol,SD=1.89),P=0.032。

临床怎么用

  • 在临床指征明确的人群中,减少预授权等行政负担可能改善糖尿病技术可及性。
  • 即使取消预授权,仍需关注残余延迟和结构性障碍对设备获取的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Because of a computer-based prior authorization (PA) centralized system failure, Medi-Cal authorities temporarily suspended PA requirements for continuous glucose monitoring (CGM) and insulin pumps, including automated insulin delivery systems, for 18 months. We assessed whether this PA-free period improved access to diabetes technology or impacted glycemic control. RESEARCH DESIGN AND METHODS: We conducted a retrospective chart review of 105 adults with type 1 diabetes in a safety net clinic across two sequential policy periods: PA-required and PA-free. Observational outcomes included device prescriptions, delays, denials, device receipt, and HbA1c. Paired t tests (α = 0.05) assessed HbA1c changes; descriptive statistics summarized access. Definitions for delay and access outcomes were standardized a priori. RESULTS: During the PA-required period, 32 CGM prescriptions were written; 46% were delayed (mean: 82 days), and 21% were denied. During the PA-free period, 27 new CGM prescriptions were written; approvals increased, and mean delay decreased to 40 days, although delays persisted. CGM use increased from 36.2% to 81.0%, and pump use increased from 16 to 25 patients. Mean HbA1c decreased from 9.1%, 76 mmol/mol (SD = 2.16), to 8.5%, 69 mmol/mol (SD = 1.89) (P = 0.032). CONCLUSIONS: Removal of PA requirements was associated with improved access to diabetes technology and clinically meaningful HbA1c reductions. Residual barriers highlight persistent structural inequities. Findings support policies that reduce administrative burden for clinically indicated populations.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Ruelas V, Bernstein M, Flores Garcia J, et al. Impact of Prior Authorization Suspension on Access to Diabetes Technology in an Underserved Population: A Retrospective Analysis. Diabetes Care. 2026. PMID: 42312902. doi:10.2337/dc26-0284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。